<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Ten children with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> underwent an allogeneic bone marrow transplantation (BMT) with an intensified conditioning regimen </plain></SENT>
<SENT sid="1" pm="."><plain>The median age of the patients was 8 years (range 2-10), and included 6 males and 4 females </plain></SENT>
<SENT sid="2" pm="."><plain>The subtype of the disease was <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA) in 4, RA with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) in 4, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e>) in 1, and juvenile <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JCML</z:e>) in 1 </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were conditioned with high-dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (12000 mg/m2), <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (120 mg/kg) and either total body irradiation (10-13.2 Gy) or <z:chebi fb="0" ids="28901">busulfan</z:chebi> (16 mg/kg or 560 mg/m2) </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="4031">Cyclosporine</z:chebi> A and/or <z:chebi fb="0" ids="44185">methotrexate</z:chebi> were used for the prophylaxis of <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) </plain></SENT>
<SENT sid="5" pm="."><plain>Engraftment was prompt in <z:hpo ids='HP_0000001'>all</z:hpo> but one patient </plain></SENT>
<SENT sid="6" pm="."><plain>Severe <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD (grade 3) (n = 1), <z:hpo ids='HP_0006515'>interstitial pneumonitis</z:hpo> (n = 1) and <z:e sem="disease" ids="C0019156" disease_type="Disease or Syndrome" abbrv="">veno-occlusive disease of the liver</z:e> (n = 1) occurred </plain></SENT>
<SENT sid="7" pm="."><plain>The disease relapsed in one patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Seven of the 10 patients were alive and disease free 2-74 months after BMT </plain></SENT>
<SENT sid="9" pm="."><plain>The disease-free survival rate at 4 years was 69 +/- 15% </plain></SENT>
<SENT sid="10" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> surviving patients were in the full performance status </plain></SENT>
<SENT sid="11" pm="."><plain>The examined children with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> tolerated this intensified conditioning regimen well </plain></SENT>
</text></document>